Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypoglycemia does not respond to dextrose infusion, several medication options are available, including diazoxide(1,2). Several side effects of diazoxide are described in the literature, including fluid retention with the risk of development of congestive heart failure(3,4). We describe a case of necrotizing enterocolitis in a patient with Beckwith-Wiedemann Syndrome with persistent neonatal hypoglycemia who was treated with increasing doses of diazoxide
We report a case of partial diazoxide responsiveness in a child with severe congenital hyperinsulina...
Neonatal hyperinsulinemic hypoglycemia must be suddenly and appropriately diagnosed and treated to p...
Necrotizing enterocolitis in full-term infants is relatively rare. When seen, it is usually associat...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
SUMMARY Seven infants with persistent neonatal hyperinsulinism were treated in Dhahran Health Centre...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
Long-term diazoxide and somatostatin analogue have been used in the treatment of persistent hyperins...
Abstract Introduction: Diazoxide is the first-line treatment used to manage infants and children wit...
Ranjit I Kylat Division of Neonatal-Perinatal Medicine and Developmental Biology, Department of Pedi...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
We report a case of partial diazoxide responsiveness in a child with severe congenital hyperinsulina...
Neonatal hyperinsulinemic hypoglycemia must be suddenly and appropriately diagnosed and treated to p...
Necrotizing enterocolitis in full-term infants is relatively rare. When seen, it is usually associat...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
SUMMARY Seven infants with persistent neonatal hyperinsulinism were treated in Dhahran Health Centre...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
Long-term diazoxide and somatostatin analogue have been used in the treatment of persistent hyperins...
Abstract Introduction: Diazoxide is the first-line treatment used to manage infants and children wit...
Ranjit I Kylat Division of Neonatal-Perinatal Medicine and Developmental Biology, Department of Pedi...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
We report a case of partial diazoxide responsiveness in a child with severe congenital hyperinsulina...
Neonatal hyperinsulinemic hypoglycemia must be suddenly and appropriately diagnosed and treated to p...
Necrotizing enterocolitis in full-term infants is relatively rare. When seen, it is usually associat...